| Active Not Recruiting | A Phase III Trial to Evaluate the Efficacy, Immunogenicity and Safety of a Recombinant Human Papillomavirus 9- NCT06866574 | Xiamen University | Phase 3 |
| Active Not Recruiting | Immunogenicity and Safety of V503 in Chinese Males 9 Through 19 Years Old (V503-053) NCT05314023 | Merck Sharp & Dohme LLC | Phase 3 |
| Unknown | Conventional Photodynamic Therapy vs. Painless Photodynamic Therapy for Small Genital Warts NCT03948321 | Shanghai Dermatology Hospital | N/A |
| Completed | Effectiveness Study of Human Papilloma Virus (HPV) Vaccines to Prevent Recurrence of Genital Warts NCT02750202 | University of Pretoria | Phase 3 |
| Unknown | Efficacy of Quadrivalent HPV Vaccine to Prevent Relapses of Genital Warts After Initial Therapeutic Response NCT03296397 | Assistance Publique - Hôpitaux de Paris | Phase 3 |
| Completed | Immunogenicity and Tolerability of Broad Spectrum Human Papillomavirus (HPV) Vaccine in Adult and Young Adult NCT03158220 | Merck Sharp & Dohme LLC | Phase 3 |
| Active Not Recruiting | Long-term Follow-up of Broad Spectrum Human Papillomavirus (HPV) Vaccine Study in Women (V503-021) NCT02653118 | Merck Sharp & Dohme LLC | — |
| Completed | Topical NVN1000 for the Treatment of External Genital and Perianal Warts NCT02462187 | Novan, Inc. | Phase 2 |
| Completed | Long Term Follow-up of HPV Vaccine in HIV (CTN 236) NCT06915779 | University of British Columbia | — |
| Completed | HPV Vaccination: Evaluation of Reminder Prompts for Doses 2 & 3 NCT02558803 | Regenstrief Institute, Inc. | N/A |
| Completed | Efficacy and Safety Profiles of SR-T100 Gel on External Genital Warts/Condyloma Acuminate(EGWs) NCT01796821 | G&E Herbal Biotechnology Co., LTD | Phase 2 |
| Completed | The Epidemiologic Study of Human Papillomavirus Infection and Related Diseases NCT02188004 | Jun Zhang | — |
| Completed | HPV Vaccination: An Investigation of Physician Reminders and Recommendation Scripts NCT02551887 | Regenstrief Institute, Inc. | N/A |
| Completed | Multivalent HPV (Human Papillomavirus) Vaccine Study in 16- to 26-Year Old Men and Women (V503-003) NCT01651949 | Merck Sharp & Dohme LLC | Phase 3 |
| Completed | Impact of HPV Vaccination Against Cervical Lesions and Genital Warts in Colombia. an Ecological Assessment NCT06700941 | Universidad Nacional de Colombia | — |
| Terminated | A RTC to Examine the Effectiveness of 400 mg of Oral Zinc Gluconate as Adjunctive Therapy for Ano-genital Wart NCT01468636 | University of British Columbia | Phase 4 |
| Completed | SR-T100 Gel Efficacy & Safety Study for Vulva Pre-cancerous Lesions & Cutaneous Condyloma NCT01676792 | National Cheng-Kung University Hospital | EARLY_Phase 1 |
| Completed | Typing of Human Papilloma Virus (HPV) From Female Genital Warts NCT01192282 | University of Cape Town | — |
| Completed | A Study of V503, a 9-valent Human Papillomavirus (9vHPV) Vaccine in Females 12-26 Years of Age Who Have Previo NCT01047345 | Merck Sharp & Dohme LLC | Phase 3 |
| Completed | Pharmacokinetic Study of Topically Applied Veregen 15% Compared With Oral Intake of Green Tea Beverage NCT01082302 | MediGene | Phase 4 |
| Completed | Human Papillomavirus (HPV) Genotypes in Genital Warts in Colombian Population NCT00847340 | La Fundacion para la Investigacion y el Desarrollo | — |
| Completed | Alternate Dosing Schedules Study for HPV Vaccine (ADS) NCT02280642 | Duke University | — |
| Completed | Alternate Dosing Schedules Study for HPV Vaccine NCT00862810 | Duke University | Phase 4 |
| Completed | Phase 3 Study of Imiquimod Creams in the Treatment of External Genital Warts NCT00735462 | Graceway Pharmaceuticals, LLC | Phase 3 |
| Completed | Safety and Effectiveness Study of Imiquimod Creams in the Treatment of External Genital Warts NCT00674739 | Graceway Pharmaceuticals, LLC | Phase 3 |
| Completed | A Study to Evaluate Tolerability and Immunogenicity of V504 Administered Concomitantly With GARDASIL (V504-001 NCT00551187 | Merck Sharp & Dohme LLC | Phase 2 |
| Completed | Broad Spectrum HPV (Human Papillomavirus) Vaccine in 16 to 26 Year Old Women (V505-001) NCT00520598 | Merck Sharp & Dohme LLC | Phase 2 |
| Completed | Broad Spectrum HPV (Human Papillomavirus) Vaccine Study in 16-to 26-Year-Old Women (V503-001) NCT00543543 | Merck Sharp & Dohme LLC | Phase 3 |
| Completed | Safety and Effectiveness Study of an Experimental Topical Ointment (GS-9191) for the Treatment of Genital Wart NCT00499967 | Gilead Sciences | Phase 1 |
| Completed | A Controlled Trial to Assess the Immunogenicity of a Proposed Paediatric Dosing Schedule of Human Papillomavir NCT00501137 | Simon Dobson | Phase 3 |
| Completed | Effectiveness Study of Gardasil on Condyloma NCT01553994 | Lisen Arnheim Dahlstrom | — |
| Completed | Broad Spectrum HPV Vaccine Dose Escalation Study (V502-002) NCT00851643 | Merck Sharp & Dohme LLC | Phase 1 |
| Completed | Study of Imiquimod Cream Prior to Ablative Therapy in External Ano-Genital Warts NCT00189293 | MEDA Pharma GmbH & Co. KG | Phase 4 |
| Completed | Study of an Investigational Vaccine in Pre-Adolescents and Adolescents (Gardasil)(V501-016) NCT00092495 | Merck Sharp & Dohme LLC | Phase 3 |
| Completed | Immunogenicity Bridge Between an Investigational Monovalent Vaccine and the Equivalent Component of Gardasil ( NCT00092482 | Merck Sharp & Dohme LLC | Phase 3 |
| Completed | Cervical Intraepithelial Neoplasm (CIN) in Women (Gardasil) (V501-015) NCT00092534 | Merck Sharp & Dohme LLC | Phase 3 |
| Completed | Study to Test the Safety of HPV Vaccine in Women (V501-011)(COMPLETED) NCT00517309 | Merck Sharp & Dohme LLC | Phase 3 |
| Completed | Cervical Intraepithelial Neoplasm (CIN)-Warts Efficacy Trial in Women (Gardasil)(V501-013)(COMPLETED) NCT00092521 | Merck Sharp & Dohme LLC | Phase 3 |